2020
DOI: 10.1016/j.smim.2020.101430
|View full text |Cite
|
Sign up to set email alerts
|

New viral vectors for infectious diseases and cancer

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1
1
1
1

Citation Types

0
61
0

Year Published

2021
2021
2024
2024

Publication Types

Select...
8
1

Relationship

0
9

Authors

Journals

citations
Cited by 70 publications
(61 citation statements)
references
References 328 publications
0
61
0
Order By: Relevance
“…In other words, viral vectors' basic operating mechanism consists of carrying the target pathogen's genetic information that is required for the development of a response in its own genome. In this way, the heterologous gene is expressed together with the vector genes during its multiplication cycle, leading to the production of the immunogenic epitopes within the target cell, hence akin to a "Trojan horse" [9][10][11][12] (Figure 1). To accomplish the necessary stealthiness and safety, some of the viral vector's non-essential genes are deleted and replaced by the desired recombinant genes to be delivered into the host cells [9,[13][14][15].…”
Section: The "Trojan Horse" Technologymentioning
confidence: 99%
“…In other words, viral vectors' basic operating mechanism consists of carrying the target pathogen's genetic information that is required for the development of a response in its own genome. In this way, the heterologous gene is expressed together with the vector genes during its multiplication cycle, leading to the production of the immunogenic epitopes within the target cell, hence akin to a "Trojan horse" [9][10][11][12] (Figure 1). To accomplish the necessary stealthiness and safety, some of the viral vector's non-essential genes are deleted and replaced by the desired recombinant genes to be delivered into the host cells [9,[13][14][15].…”
Section: The "Trojan Horse" Technologymentioning
confidence: 99%
“…This therapeutic regimen has recently entered clinical trials. The use of virus vector-based vaccine strategies has been extensively reviewed in other publications [ 201 , 209 , 210 ].…”
Section: Delivery Strategiesmentioning
confidence: 99%
“…While viral vectors are a flexible platform, allowing the rapid adaption to new antigen targets of emerging pathogens, they might suffer from pre-existing immunity against the vector, neutralizing the vaccine before cellular uptake. This is a particular problem for booster vaccinations using the same viral vector and also the relatively costly cell-based production of viral vectors present a challenge [17]. In the case of DNA vaccines, the antigen-encoding DNA is introduced directly or lipid-encapsulated into host cells.…”
Section: Next-generation Nucleic Acid-based Vaccinesmentioning
confidence: 99%
“…For intracellular pathogens, the development of effective vaccines has long been held back by a lack of antigen knowledge along with the inability of most vaccine platforms to elicit strong cytotoxic responses. The latter can now be overcome by next-generation vaccines, including viral vector, DNA, and mRNA vaccines that induce both humoral and cytotoxic immune responses and allow relatively fast development times (Box 1, and reviewed in detail in [15][16][17]). All three approaches introduce the genetic information encoding the actual antigen into host cells for intracellular antigen synthesis, resulting in elevated cytotoxic immune responses.…”
mentioning
confidence: 99%